Glutamate in Cerebral Tissue of Asphyxiated Neonates during the First Week of Life Demonstrated in vivo Using Proton Magnetic Resonance Spectroscopy
We tested the hypothesis that glutamate (Glx) levels as demonstrated by proton magnetic resonance spectroscopy ( 1 H-MRS) are elevated in brain tissue of neonates with severe hypoxic-ischemic encephalopathy (HIE). Studies were performed in 26 neonates (median gestational age 40.5 weeks, range 36.7–4...
Gespeichert in:
Veröffentlicht in: | Biology of the neonate 2001-01, Vol.79 (3-4), p.254-257 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | We tested the hypothesis that glutamate (Glx) levels as demonstrated by proton magnetic resonance spectroscopy ( 1 H-MRS) are elevated in brain tissue of neonates with severe hypoxic-ischemic encephalopathy (HIE). Studies were performed in 26 neonates (median gestational age 40.5 weeks, range 36.7–42.4 weeks; median birth weight 3,360 g, range 2,180–4,200 g). The median postnatal age at the time of testing was 2.5 days (range 1–7 days). HIE was scored according to Sarnat as grade I (n = 4), grade II (n = 15) or grade III (n = 7). Results for neonates with mild to moderate HIE (group 1) were compared to those with severe HIE (group 2). After magnetic resonance imaging, 1 H-MRS was performed in a single volume of interest including the basal ganglia. An echo time of 31 ms was used. After curve-fitting procedures, peak area ratios of different brain metabolites were calculated. The median total Glx/N-acetylaspartate ratio was 1.21 (range 0.64–3.25) in group 1 versus 1.55 (range 1.10–2.75) in group 2 (p = 0.035). The median total Glx/choline ratio was 1.33 (range 0.71–2.52) in group 1 versus 2.14 (range 1.21–3.55) in group 2 (p = 0.019). We concluded that during the first days of life, Glx was elevated in the basal ganglia of neonates with severe HIE. |
---|---|
ISSN: | 1661-7800 0006-3126 1661-7819 1421-9727 |
DOI: | 10.1159/000047101 |